Page 53 - ARNM-2-4

Advances in Radiotherapy &

Nuclear Medicine

ORIGINAL RESEARCH ARTICLE
Efficacy and safety of stereotactic radiotherapy

in oligometastases

Huan Dong 1† , Rong Li 1,2† , He-Qing Huang 1 , Xing-Hua Chen ,
1
Zi-Yan Zhou 3 , and Min Kang *
1
1 Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University,
Radiation Oncology Clinical Medical Research Center of Guangxi, 6 Shuangyong Road, Nanning,
Guangxi Zhuang Autonomous Region, China
2 Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University,
Nanning, Guangxi Zhuang Autonomous Region, China
3 Key Laboratory of Early Prevention and Treatment for Regional High-Frequency Tumor (Guangxi
Medical University), Ministry of Education, Nanning, Guangxi Zhuang Autonomous Region, China

Abstract

Distant metastasis remains a leading cause of treatment failure in patients with cancer.
While salvage treatments such as surgery, targeted therapy, and immunotherapy
provide some benefits, they have inherent limitations. This study examines the efficacy
and safety of stereotactic radiotherapy (SRT) in managing oligometastatic tumors. We
retrospectively analyzed data from 96 patients with oligometastatic tumors who were
treated with SRT at the Department of Radiotherapy of the First Affiliated Hospital of
† These authors contributed equally Guangxi Medical University between September 2019 and March 2023. Descriptive
to this work.
statistics were used to analyze patient characteristics, tumor response, and survival
*Corresponding author: outcomes, whereas a single-sample ratio test was used to compare SRT efficacy across
Min Kang
(kangmin@gxmu.edu.cn) different tumor sites. Kaplan–Meier analysis was used to determine progression-free
survival (PFS) and overall survival (OS). Three months post-treatment, the complete
Citation: Dong H, Li R, Huang
H, Chen X, Zhou Z, Kang M. response, partial response, stable disease, and progressive disease rates were 26.32%,
Efficacy and safety of stereotactic 50.00%, 21.05%, and 2.63% for liver oligometastases; 0.00%, 39.13%, 43.48%, and
radiotherapy in oligometastases. 17.39% for lung oligometastases; and 8.57%, 62.86%, 25.71%, and 2.86% for brain
Adv Radiother Nucl Med. oligometastases, respectively. The objective response rate was 65.62%, and the
2024;2(4):3391.
doi: 10.36922/arnm.3391 disease control rate was 93.75%. The median PFS was 18 months, and the median
OS was 27 months. The primary lesions were mainly located in the liver and lungs.
Received: April 9, 2024
Compared with previous studies where stereotactic ablative body radiotherapy
Accepted: June 28, 2024 achieved a median OS of 16 months for liver metastases and surgery yielded an OS of
Published Online: November 13, 7 – 24 months for non-small cell lung cancer with brain metastases, our SRT outcomes
2024 were significantly improved. Adverse events (≥grade 3), primarily hematological
Copyright: © 2024 Author(s). toxicity, occurred in only 5.21% of patients. SRT was both effective and well-tolerated
This is an Open-Access article among patients with oligometastatic tumors, offering a promising treatment option.
distributed under the terms of the
Creative Commons Attribution
License, permitting distribution, Keywords: Stereotactic radiotherapy; Oligometastases; Efficacy; Safety
and reproduction in any medium,
provided the original work is
properly cited.
Publisher’s Note: AccScience
Publishing remains neutral with 1. Introduction
regard to jurisdictional claims in
published maps and institutional With rapid advancements in comprehensive cancer treatment, the prognosis of patients
affiliations with cancer has significantly improved. However, distant metastasis remains the main

Volume 2 Issue 4 (2024) 1 doi: 10.36922/arnm.3391